OnconetixONCO.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, Onconetix (ONCO.O) trades at a negative P/E (-0.25x, due to a recent net loss), P/B of 0.19x, P/S of 3.89x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 13th percentile over the trailing 10Y window (vs. 23rd percentile over 3Y); P/S sits at the 58th percentile over the trailing 10Y window (vs. 58th percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 3rd percentile within its industry and the 3rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 68.32%, ranking at the 94th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Onconetix operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: ONCO · ONCO
Want the full picture on whether Onconetix (ONCO.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -0.25 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 0.19 | ||||||
| P/S (TTM) | 3.89 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 68.32% |